发明名称 |
Modulators of HEC1 activity and methods therefor |
摘要 |
Compounds, compositions, and methods for modulation of Hec1/Nek2 interaction are provided. Especially preferred compounds disrupt Nek2/Hec1 binding and are therefore useful as chemotherapeutic agent for neoplastic diseases. |
申请公布号 |
US9409902(B2) |
申请公布日期 |
2016.08.09 |
申请号 |
US201414527087 |
申请日期 |
2014.10.29 |
申请人 |
Taivex Therapeutics Corporation |
发明人 |
Lau Johnson;Huang Jiann-Jyh |
分类号 |
A61K31/4436;C07D417/14;A61K31/427;A61K31/4439;A61K31/496;A61K31/501;A61K31/506;A61K31/5377;C07D417/12;A61K31/426;A61K31/444;A61K31/4545;C07D277/44 |
主分类号 |
A61K31/4436 |
代理机构 |
Lewis Roca Rothgerber Christie LLP |
代理人 |
Lewis Roca Rothgerber Christie LLP |
主权项 |
1. A method of treating a neoplastic disease, comprising:
administering to a mammal in need thereof a pharmaceutical composition comprising a compound having a structure according to Formula I R1 is alkyl, ORa, SRa, or —S(O)2Ra; Ra is alkyl, or aryl substituted with alkoxy; R2 and R3 are independently alkyl; R4 is hydrogen; R5 is pyridyl optionally substituted with alkyl, fluoroalkyl, halogen, or alkoxy; wherein the compound is present in the composition an amount effective to disrupt Hec1/Nek2 binding in the mammal when the composition is administered to the mannal; and wherein the neoplastic disease is selected from the group consisting of breast cancer, prostate cancer, cervical cancer and leukemia. |
地址 |
Taipei TW |